Sandostatin LAR10 mg/vial

Sandostatin LAR is a synthetic somatostatin analog used for several hormone-related conditions. Its indications are classified below by strength of evidence.

Established / FDA-approved uses

• Acromegaly: to reduce growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels in patients who have not responded adequately to surgery, radiotherapy, or dopamine agonist therapy, or as an interim measure until other treatments take effect.
• Carcinoid tumors: for the symptomatic treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.
• VIPomas: for symptomatic treatment of profuse watery diarrhea associated with VIP-secreting (vasoactive intestinal peptide-secreting) tumors.

Guideline-supported / adjunct uses

• Acute variceal bleeding: as an adjunct to endoscopic therapy in the management of bleeding esophageal varices, used to reduce splanchnic blood flow and portal pressure until definitive treatment is performed.
• Neuroendocrine tumors (e.g., gastroenteropancreatic NETs): as part of symptom control and, in radiolabeled form, as a diagnostic/therapeutic tool in specialist oncology settings.

Off-label / specialist uses

• Severe or refractory diarrhea in other settings (e.g., chemotherapy-induced, AIDS-related, dumping syndrome, short bowel syndrome), congenital hyperinsulinism, and certain pancreatic/gastrointestinal fistulas — used under specialist supervision as these are not primary FDA-approved indications.

Use of Sandostatin LAR for any indication should be directed and monitored by a physician experienced in the relevant condition.

Each formulation of Octreotide Acetate contains octreotide (as the acetate salt), a synthetic octapeptide analogue of the naturally occurring hormone somatostatin, as the active pharmaceutical ingredient. It is available as:

• A short-acting injection solution (for subcutaneous or intravenous use), typically supplied in strengths such as 50 mcg/mL, 100 mcg/mL, 200 mcg/mL, 500 mcg/mL, or 1000 mcg/mL.
• A long-acting release (depot) suspension for deep intramuscular injection, supplied as a powder for suspension in single-use kits (e.g., 10 mg, 20 mg, 30 mg strengths) with accompanying diluent.

Excipients vary by manufacturer and formulation; refer to the specific product's package insert for a complete list of inactive ingredients.

Sandostatin LAR is a synthetic cyclic octapeptide that mimics the biological actions of the naturally occurring hormone somatostatin but with a longer duration of action. It is used to suppress excessive secretion of growth hormone and various gastrointestinal and pancreatic hormones (such as insulin, glucagon, gastrin, and vasoactive intestinal peptide) that drive the symptoms of certain endocrine and neuroendocrine tumors. Sandostatin LAR is administered by injection and is available in a short-acting form for multiple daily doses and a long-acting depot form for once-monthly administration.

Somatostatin analog (hormone/growth hormone-inhibiting agent); used in the management of acromegaly and neuroendocrine tumor syndromes.

Octreotide Acetate acts as an agonist at somatostatin receptors, predominantly subtypes SSTR2 and SSTR5, which are found on pituitary, pancreatic, gastrointestinal, and many neuroendocrine tumor cells.

• It inhibits the secretion of growth hormone from the pituitary, and reduces IGF-1 levels in acromegaly.
• It suppresses secretion of serotonin, gastrin, vasoactive intestinal peptide (VIP), insulin, glucagon, secretin, motilin, and pancreatic polypeptide, which underlies its benefit in carcinoid syndrome and VIPoma.
• It reduces splanchnic blood flow and portal venous pressure, which is the basis for its adjunctive use in variceal hemorrhage.

Octreotide Acetate is roughly 45 times more potent than natural somatostatin in inhibiting growth hormone release and has a substantially longer half-life, allowing for practical dosing intervals. Following subcutaneous injection it is rapidly and completely absorbed, reaching peak plasma concentrations within about 30 minutes; the short-acting form has an elimination half-life of approximately 1.5–2 hours, while the long-acting depot formulation is designed for slow, sustained release over about 4 weeks.

Short-acting injection: may be given by subcutaneous injection (preferred for chronic self-administered use) or by slow intravenous injection/infusion (typically used in acute/hospital settings, e.g., variceal bleeding). Subcutaneous injection sites should be rotated to avoid local irritation, and the solution should be at room temperature before injection to reduce discomfort. Patients or caregivers may be trained by a healthcare professional to self-administer subcutaneous doses.

Long-acting depot form: must only be reconstituted and administered by a trained healthcare professional as a deep intramuscular (gluteal) injection; it must never be given intravenously or subcutaneously. See Reconstitution for preparation details.

Do not change the route, dose, or frequency of Sandostatin LAR without medical advice.

Sandostatin LAR has several clinically significant drug interactions:

• Insulin and oral hypoglycemic agents: Sandostatin LAR alters glucose homeostasis (can cause both hyperglycemia and hypoglycemia); doses of insulin or oral antidiabetic drugs often need adjustment, with close blood glucose monitoring.
• Cyclosporine: Sandostatin LAR may reduce cyclosporine absorption/blood levels, which can increase the risk of transplant rejection; cyclosporine levels should be monitored and the dose adjusted as needed.
• Bromocriptine: co-administration with Sandostatin LAR increases bromocriptine bioavailability; dose adjustment of bromocriptine may be needed.
• Beta-blockers, calcium channel blockers, and other agents affecting heart rate/conduction: Sandostatin LAR can cause bradycardia and conduction disturbances; concurrent use requires caution and monitoring, with dose adjustment of the other agent if necessary (see Precautions and Warnings for cardiac effects).
• Drugs metabolized by cytochrome P450 enzymes (e.g., certain lipophilic beta-blockers): Sandostatin LAR may alter clearance of some hepatically metabolized drugs due to growth hormone suppression; clinical monitoring is advised.
• Lutetium Lu 177 dotatate and other radiolabeled somatostatin analogs: short-acting Sandostatin LAR should be discontinued at least 24 hours, and long-acting depot forms discontinued for a longer defined period, before each dose, as octreotide can competitively block receptor binding.

Inform your physician of all medicines, supplements, and herbal products you are taking before starting Sandostatin LAR.

Side effects of Sandostatin LAR are generally dose-related and often diminish with continued use. Common and important effects include:

• Gastrointestinal: diarrhea, loose stools, abdominal pain/discomfort, nausea, vomiting, constipation, and flatulence (among the most frequently reported effects).
• Gallbladder/biliary: gallstone (cholelithiasis) formation or biliary sludge with long-term use (see Precautions and Warnings).
• Glucose metabolism: hyperglycemia or hypoglycemia (see Precautions and Warnings).
• Cardiac: bradycardia, conduction abnormalities, and rarely arrhythmias (see Precautions and Warnings).
• Endocrine: hypothyroidism or subclinical thyroid function changes with long-term use.
• Local reactions: pain, stinging, or swelling at the injection site.
• Other: headache, dizziness, fatigue, and rarely hypersensitivity/anaphylactoid reactions.

Contact your physician promptly if you experience severe abdominal pain, signs of gallbladder problems (e.g., right upper abdominal pain, jaundice), unusual heart rhythm, or signs of severe allergic reaction while using Sandostatin LAR.

Pregnancy: Data on the use of Sandostatin LAR in human pregnancy are limited. Animal studies have not shown clear evidence of fetal harm at clinically relevant doses, but human safety has not been firmly established. Sandostatin LAR should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus; use should be under close physician supervision, and women of childbearing potential should discuss appropriate contraception with their doctor, as fertility may improve during treatment of acromegaly.

Lactation: It is not well established whether Sandostatin LAR passes into human breast milk in clinically significant amounts. Because of the potential for adverse effects in a nursing infant, a decision should be made in consultation with a physician whether to discontinue breastfeeding or discontinue the medicine, taking into account the importance of treatment to the mother.

Use Sandostatin LAR only under the supervision of a physician experienced in managing the underlying condition (endocrinology, oncology, or gastroenterology as appropriate), with the following precautions:

• Gallbladder disease: Long-term use is commonly associated with gallstone formation or biliary sludge; periodic gallbladder ultrasound monitoring may be considered, particularly with prolonged therapy.
• Glucose homeostasis: Sandostatin LAR can cause hyperglycemia or hypoglycemia by altering insulin, glucagon, and GH secretion. Blood glucose should be monitored regularly, especially in patients with diabetes mellitus, and antidiabetic therapy adjusted as needed.
• Cardiac conduction: Bradycardia and conduction abnormalities (including QT interval changes) have been reported; use caution in patients with pre-existing cardiac disease or those taking other drugs known to affect heart rate or cardiac conduction, and monitor as clinically indicated.
• Thyroid function: Long-term use may suppress thyroid function; periodic monitoring of thyroid function tests is reasonable during extended therapy.
• Vitamin B12 deficiency: Long-term use has been associated with reduced vitamin B12 levels; periodic monitoring is reasonable.
• Renal and hepatic impairment: Drug clearance may be reduced; dose adjustment of the maintenance dose may be required (see Use in Special Populations).

Do not stop, skip, or change your dose of Sandostatin LAR without consulting your physician, and keep all scheduled monitoring appointments.

Reports of overdose with Sandostatin LAR have been associated with effects such as irregular heartbeat, low blood pressure, and gastrointestinal or pancreatic disturbances. If an overdose of Sandostatin LAR is suspected, seek immediate medical attention or contact a poison control center right away. Treatment is supportive and should be provided in a medical facility with appropriate monitoring; there is no specific antidote. Do not attempt to manage a suspected overdose at home.

Store unopened Sandostatin LAR injection in a refrigerator at 2–8°C (36–46°F), protected from light. Unopened vials/ampoules may generally be kept at room temperature (up to 30°C) for a limited period (check the specific product's labeling, typically up to about 14 days) if refrigeration is not available, but should be protected from direct light and excessive heat. Do not freeze. Discard any opened multi-dose vial according to the product labeling (typically within 14 days of opening). Keep all forms of Sandostatin LAR out of the reach of children, and do not use beyond the expiry date.

Pediatric use: Safety and efficacy of Sandostatin LAR have not been well established in children, particularly under 6 years of age; use only under specialist supervision when the potential benefit outweighs the risk, with close monitoring (see Pediatric Uses).

Elderly: No significant age-related change in efficacy has been noted, but elderly patients often have reduced hepatic or renal function, so cautious dose titration is recommended.

Renal impairment: Elimination half-life may be prolonged in patients with renal impairment, including those on dialysis; maintenance dose adjustment may be needed.

Hepatic impairment: Clearance of Sandostatin LAR may be reduced in patients with liver cirrhosis; dose adjustment and closer monitoring are advised.

The duration of treatment with Sandostatin LAR depends on the indication and clinical response. In acromegaly, treatment is usually long-term (often indefinite), with periodic reassessment of growth hormone and IGF-1 levels (e.g., every 6–12 months) to confirm continued benefit and appropriate dosing. In carcinoid syndrome and VIPoma, treatment continues as long as it provides symptomatic benefit, with periodic clinical review. In acute variceal bleeding, Sandostatin LAR is typically used for a short course (commonly up to 5 days) as an adjunct to endoscopic and other definitive therapy. Any decision to continue, adjust, or stop treatment should be made by the treating physician.

The long-acting release (depot) formulation of Sandostatin LAR is supplied as a sterile powder that must be reconstituted with the accompanying diluent immediately before administration, and only by a trained healthcare professional. Reconstitution generally involves: allowing the kit to reach room temperature, adding the supplied diluent to the vial, gently mixing (not shaking vigorously) until a uniform suspension is formed, and drawing up and injecting the suspension promptly, as it cannot be stored once reconstituted. The reconstituted suspension must be administered only by deep intramuscular (gluteal) injection immediately after preparation; it must never be given intravenously or subcutaneously. The short-acting injectable solution of Sandostatin LAR is supplied ready-to-use and does not require reconstitution.

Somatostatin analogs; growth hormone-inhibiting hormone analogs.

Octreotide Acetate binds with high affinity to somatostatin receptors (mainly SSTR2 and SSTR5) on target cells in the pituitary gland, pancreas, gastrointestinal tract, and various neuroendocrine tumors. Receptor binding inhibits the release of growth hormone, insulin, glucagon, gastrin, vasoactive intestinal peptide, serotonin, and several other gastroenteropancreatic hormones. This suppression of excessive hormone secretion underlies its effects in reducing GH/IGF-1 levels in acromegaly and controlling secretory diarrhea and flushing in carcinoid syndrome and VIPoma. Because it is more resistant to enzymatic degradation than natural somatostatin, Octreotide Acetate has a considerably longer duration of action.

The safety and efficacy of Sandostatin LAR have not been well established in pediatric patients, and it is not FDA-approved for routine use in children under 6 years of age; some serious adverse events have been reported in very young children (particularly under 2 years) receiving octreotide off-label. When Sandostatin LAR is used in children (e.g., for congenital hyperinsulinism or other specialist-directed indications), it should be prescribed and closely monitored by a pediatric specialist, with dosing individualized based on body weight and clinical response, and with careful attention to growth, glucose levels, and gastrointestinal tolerance.